ACTA NEUROPHARMACOLOGICA››2020,Vol. 10››Issue (1): 47-53.DOI:10.3969/j.issn.2095-1396.2020.01.010
Previous ArticlesNext Articles
HE Pan，LIU Yue-tao，DU Guan-hua，QIN Xue-mei
Online:2020-02-26Published:2020-02-26Contact:秦雪梅，女，教授，博士生导师；研究方向：中药药理与新药研发；Tel: +86-0351-7018379，E-mail: qinxm@sxu.edu.cn 杜冠华，男，教授，博士生导师；研究方向：新药研发及神经药理学；E-mail: dugh@imm.ac.cnAbout author:何盼，女，博士研究生；研究方向：中药药理；E-mail：yxhepan@163.comSupported by:
HE Pan, LIU Yue-tao, DU Guan-hua, QIN Xue-mei. Research Advances in Sarcopenia[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(1): 47-53.
[1] 杜艳萍, 朱汉民. 肌少症的诊疗和防治研究[J]. 中华骨质疏松和骨矿盐疾病杂志, 2014, 7(1): 1-8. [2] Stefan D Anker, John E Morley, Stephan von Haehling.Welcome to the ICD-10 code for sarcopenia[J]. J Cachexia, Sarcopenia and Muscle, 2016, 7(5): 512-514. [3] 于宝海, 吴文娟. 2018 欧洲肌少症共识解读[J]. 河北医科大学学报, 2019, 40(4): 373-379, 384. [4] 李亚奥, 修双玲, 王立. 中老年男性2型糖尿病患者肌少症与骨密度的相关性研究[J]. 首都医科大学学报, 2020, 41(1): 119-124. [5] Tournadre A, Vial G, Capel F,et al. Sarcopenia[J]. Joint Bone Spine, 2019, 86(3): 309-314. [6] 严淑, 陆亚华, 汪良芝. 老年肌少症的诊治和研究新进展[J]. 中国老年学杂志, 2018, 38 (22): 5610-5613. [7] Young Nam Kwon, Sung-Sang Yoon.Sarcopenia: neurological point of view[J]. J Bone Metabolism, 2017, 24(2): 83-89. [8] Drey M, Grösch C, Neuwirth C,et al. The motor unit number index (MUNIX) in sarcopenic patients[J]. Experimental Gerontology, 2013, 48(4): 381-384. [9] Mikael Altun, Henrike C Besche, Herman Overkleeft,et al.Muscle wasting in aged, sarcopenic rats is associated with enhanced activity of the ubiquitin proteasome pathway[J]. J Biological Chemistry, 2010, 285(51): 39597-39608. [10] 王今越, 王小虹, 冯维斗. IRS1, Akt, FOXO1在少肌症发生及其运动性缓解中的作用[J]. 成都体育学院学报, 2012, 38(7): 86-91. [11] Sebastiaan Dalle, Lenka Rossmeislova, Katrien Koppo.The role of inflammation in age-related sarcopenia[J]. Frontiers in Physiology, 2017, 8: 1045. [12] Laura A Schaap, Saskia M F Pluijm, Dorly J H Deeg,et al.Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength[J]. J Gerontology Series A: Biomedical Sciences and Medical Sciences, 2009, 64(11): 1183-1189. [13] 王今越, 王小虹, 冯维斗. p38, NF-κB, IL-6在少肌症发生及其运动性缓解中的作用[J]. 山东体育学院学报, 2012, 28(4): 51-56. [14] 林白阳. 老年 COPD 患者血清 IL-6, IL-10水平与肌少症的关系[D]. 太原：山西医科大学, 2019. [15] Aphrodite Vasilaki, Malcolm J Jackson.Role of reactive oxygen species in the defective regeneration seen in aging muscle[J]. Free Radical Biology and Medicine, 2013, 65: 317-323. [16] Adam P W Johnston, Michael De Lisio, Gianni Parise.Resistance training, sarcopenia, and the mitochondrial theory of aging[J]. Applied Physiology, Nutrition, and Metabolism, 2007, 33(1): 191-199. [17] Ramy K A Sayed, Marisol Fernández-Ortiz, Maria E Diaz-Casado,et al.Lack of NLRP3 inflammasome activation reduces age-dependent sarcopenia and mitochondrial dysfunction, favoring the prophylactic effect of melatonin[J]. J Gerontology: Series A, 2019, 74(11): 1699-1708. [18] 梁计陵, 谢金凤, 王岑依, 等. 运动诱导细胞自噬在老年肌少症康复中的研究进展[J]. 中国康复理论与实践, 2019, 25(3): 334-337. [19] Tomonori Sato, Yoshiaki Ito, Takashi Nagasawa.L-Lysine suppresses myofibrillar protein degradation and autophagy in skeletal muscles of senescence-accelerated mouse prone 8[J]. Biogerontology, 2017, 18(1): 85-95. [20] Richie Barclay, Nicholas A Burd, Christopher Tyler,et al.The role of the IGF-1 signalling cascade in muscle protein synthesis and anabolic resistance in ageing skeletal muscle[J]. Frontiers in Nutrition, 2019, 6: 146. [21] Silvia Giovannini, Emanuele Marzetti, Stephen E Borst,et al.Modulation of GH/IGF-1 axis: potential strategies to counteract sarcopenia in older adults[J]. Mechanisms of Ageing and Development, 2008, 129(10): 593-601. [22] Mee-Sup Yoon.mTOR as a key regulator in maintaining skeletal muscle mass[J]. Frontiers in Physiology, 2017, 8:788. [23] Olivier Le Bacquer, Kristell Combe, Veronique Patrac,et al.4E-BP1 and 4E-BP2 double knockout mice are protected from aging-associated sarcopenia[J]. J Cachexia, Sarcopenia and Muscle, 2019, 10, 696-709. [24] 金晶, 冯祎中, 黄伟, 等. 运动通过激活卫星细胞功能延缓和改善骨骼肌衰减症的研究进展[J]. 体育科学, 2019, 39(8): 73-80. [25] 卜凡. 耐力运动经AMPK介导的自噬维持老年小鼠骨骼肌卫星细胞干细胞属性[D]. 重庆: 重庆医科大学, 2019. [26] Parag Kundu, Eran Blacher, Eran Elinav,et al.Our gut microbiome: the evolving inner self[J]. Cell, 2017, 171(7): 1481-1493. [27] Martina Casati, Evelyn Ferri, Domenico Azzolino,et al.Gut microbiota and physical frailty through the mediation of sarcopenia[J]. Experimental Gerontology, 2019, 124: 110639. [28] Melouane, Aicha Ghanemi, Abdelaziz Yoshioka,et al.Functional genomics applications and therapeutic implications in sarcopenia[J]. Mutation Research/Reviews in Mutation Research, 2019, 781, 175-185. [29] Iryna Rusanova, Jose Fernandez-Martinez, Marisol Fernandez-Ortiz,et al.Involvement of plasma miRNAs, muscle miRNAs and mitochondrial miRNAs in the pathophysiology of frailty[J]. Experimental Gerontology, 2019, 124: 110637. [30] Darren G Candow, Scott C Forbes, Phillip D Chilibeck,et al.Variables influencing the effectiveness of creatine supplementation as a therapeutic intervention for sarcopenia[J]. Frontiers in Nutrition, 2019, 6: 124. [31] Francisco Martinez-Arnau, Fonfria-Vivas, Omar Cauli.Beneficial effects of leucine supplementation on criteria for sarcopenia: a systematic review[J]. Nutrients, 2019, 11(10): 2504. [32] Mareike S Pötsch, Anika Tschirner, Sandra Palus,et al.The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats[J]. J Cachexia, Sarcopenia and Muscle, 2014, 5(2): 149-158. [33] Peter J Snyder, Helen Peachey, Peter Hannoush,et al.Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age[J]. J Clinical Endocrinology & Metabolism, 1999, 84(8): 2647-2653. [34] Deepa Sumukadas, Miles Witham, Allan D Struthers,et al.Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial[J]. Cmaj, 2007, 177(8): 867-874. [35] 魏静, 魏凯善, 罗敏, 等. 从“脾”论治肌肉减少症[J]. 中医药临床杂志, 2019, 31 (7): 1282-1284. [36] 毛智慧, 刘晓亭, 张欢, 等. 健运脾胃法干预老年肌肉衰减综合征之机理探讨[J]. 辽宁中医杂志, 2017, 44(8): 1631-1634. [37] 梁清月, 王仲, 刘戎, 等. 加减八珍汤联合营养支持治疗老年骨骼肌减少症疗效观察[J]. 中国中西医结合杂志, 2019, 39(7): 821-825. [38] 温春瑜, 陈颖颖, 彭鹏, 等. 补中益气汤加减辅助治疗老年肌少症的临床疗效观察[J]. 实用中西医结合临床, 2018, 18(7): 72-73. [39] 任璇璇, 姚惠, 汪涛. 八珍汤联合基础干预治疗老年肌少症临床疗效观察[J]. 中国现代医生, 2016, 54(16): 127-130. [40] 徐划萍, 金国琴, 龚张斌, 等. 补肾益气方药延缓骨骼肌衰老的实验研究[J]. 中国临床药理学杂志, 2015, 31(1): 63-66. [41] 王新梅. 天麻多糖延缓D-半乳糖诱导小鼠骨骼肌衰老的实验研究[D]. 遵义：遵义医科大学, 2019. [42] 李郡, 汪双双, 杨晓军, 等. 从86例处方浅谈邓铁涛教授治疗脾胃肌肉疾病用药规律特点[J]. 时珍国医国药, 2015, 26(7): 1742-1743. [43] 鲁飞翔. 肌肉衰减综合征小鼠模型的建立及相关分子和功能的评价[D]. 锦州：锦州医科大学, 2017. [44] 王丛丛. 尿石素 B 对地塞米松诱导的肌肉衰减综合征小鼠模型的影响[D]. 锦州：锦州医科大学, 2018. [45] 王月兵. 抗阻力运动结合肌酸补充对肌肉衰减综合征模型小鼠的影响[D]. 锦州：锦州医科大学, 2017. [46] 王全全. 人脐带华通氏胶间充质干细胞治疗肌肉衰减综合征的实验研究[D]. 济南: 山东大学, 2018. [47] 连雯雯, 刘艾林, 杜冠华. DL0410改善D-半乳糖致衰老小鼠认知功能的线粒体保护机制研究[J]. 神经药理学报, 2017, 7(02): 60. [48] 王雪飞, 康金森. 香茅精油对D-半乳糖联合三氯化铝致老年痴呆小鼠的保护作用[J]. 神经药理学报, 2017, 7(02): 38-39. [49] 王婧. D-半乳糖对肌肉衰减综合征的诱导效应和抗肌肉衰减因子研究[D]. 北京：中国疾病预防控制中心, 2019. [50] Mohammed Mukhram Azeemuddin, Chamallamudi Mallikarjuna Rao, Mohamed Rafiq,et al.Pharmacological investigation of ‘HIM-CHX’: A herbal combination in the experimental muscle wasting condition[J]. Experimental Gerontology, 2019, 125: 110663. [51] Meador B M, Mirza K A, Tian M,et al.The green tea polyphenol Epigallocatechin-3-Gallate (EGCg) attenuates skeletal muscle atrophy in a rat model of sarcopenia[J]. The J Frailty & Aging, 2015, 4(4): 209-215. [52] Deepa Sathyaseelan, Holly Van Remmen, Susan V Brooks,et al.Accelerated sarcopenia in Cu/Zn superoxide dismutase knockout mice[J]. Free Radical Biology and Medicine, 2019, 132: 19-23. |
| [1] | LEI Luo-chun, AI Ying, YANG Jun-ying, ZHENG Wei.Effect of Routine and Optimized Treatment in ICU on Cerebral Resuscitation in Patients with Post-Cardiac Arrest Syndrome#br#[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(4): 1-4. |
| [2] | ZHANG Li-huan, CHU Bao, ZHANG Xiao-yan, SUN Ying-ru, GONG Chun-dong, WANG He-bo.Research Progress of Magnesium in Pathogenesis and Treatment of Migraine[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(1): 29-33. |
| [3] | XING Yuan，ZHANG Nan，ZHANG Wei，REN Lei-ming.Neurotoxicity and Prevention of Local Anesthetics in Central Nervous System[J]. Acta Neuropharmacologica, 2018, 8(3): 15-. |
| [4] | DU Guan-hua，ZHANG Wen，DU Li-da，MA Yin-zhong，LI Li，WANG Yue-hua.New Strategies for the Drug Development of Anti-cerebral Ischemia —Advances in the Etiology and Drug Development of Acute Cerebral Ischemia[J]. Acta Neuropharmacologica, 2018, 8(1): 1-8. |
| [5] | LIU Nuo，WANG Zhen-zhen，CHEN Nai-hong.The Role of Gut Flora in the Pathogenesis of Alzheimer’s Disease[J]. Acta Neuropharmacologica, 2017, 7(5): 28-. |
| [6] | GAO Zhi-hong1，ZUO Ya-qi2，ZHANG Xiao-li1.A New Idea of Astragaloside-Induced Bone Marrow Mesenchymal Stem Cells in the Treatment of Parkinson’s Disease[J]. Acta Neuropharmacologica, 2017, 7(5): 39-44. |
| [7] | GAO Jin-chao， ZHAO Wen-juan， YIN Ming.Progress in the Relationship of Apolipoprotein E4 on Alzheimer’s Disease[J]. Acta Neuropharmacologica, 2016, 6(6): 31-39. |
| [8] | LUO Lin-ming, JI Yi-na, CHEN Nai-hong.Research Progress on the Effect of Neural Stem Cells in the Occurrence and Development of Glioma[J]. Acta Neuropharmacologica, 2015, 5(5): 28-33. |
| [9] | XUE Zhan-xia，GAO Yong-shan.Research Progress of Postoperative Delirium[J]. Acta Neuropharmacologica, 2014, 4(4): 20-27. |
| [10] | WU Zhi-gang，SHEN Li-xia.Treatment for Lower Urinary Tract Dysfunction in Patients with Parkinson’s Disease[J]. Acta Neuropharmacologica, 2014, 4(4): 36-41. |
| [11] | LIU Feng-xi, NIU Kai, XUE Gui-ping.The Therapeutic Progress of Vascular Dementia in Terms of Modern Medicine and Chinese Traditional Treatment[J]. Acta Neuropharmacologica, 2014, 4(1): 29-33. |
| [12] | WANG Zhen-zhen, CHEN Nai-hong.Depression and Inflammation[J]. Acta Neuropharmacologica, 2013, 3(5): 27-37. |
| [13] | LIU Hong-bin，WU Hai-xia.Overview of the Pathogenesis and Animal Models of Alzheimer's Disease[J]. Acta Neuropharmacologica, 2013, 3(4): 14-22. |
| [14] | LIU Zhi-jun.Epidemiology and Pharmacotherapy of Adult Attention Deficit/Hyperactivity Disorde: Current Status[J]. Acta Neuropharmacologica, 2012, 2(5): 31-39. |
| [15] | JIN Miao, AN Hong-mei.Animal Models of Alzheimer’s Disease and Pharmacotherapeutics[J]. Acta Neuropharmacologica, 2011, 1(6): 28-36. |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||
